Pre-made Modotuximab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-353

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-353 Category Tag

Product Details

Pre-Made Modotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Modotuximab (INN; formerly zatuximab) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER1.

Products Name (INN Index)

Pre-Made Modotuximab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody

INN Name

Modotuximab

Target

EGFR

Format

Whole mAb

Derivation

Chimeric (Mouse/Human)

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2012

Companies

Symphogen,Merck

Conditions Approved

NA

Conditions Active

Colorectal cancer,Glioma,Non-small cell lung cancer

Conditions Discontinued

Head and neck cancer,Oesophageal cancer

Development Tech

NA

Previous Name

Zatuximab

Gm Offical Target Name

EGFR

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide